Bellicum pharmaceuticals, inc. proposes amended and restated certificate of incorporation

Bellicum pharmaceuticals, inc. at its special meeting to be held on january 15, 2020 proposed the company's amended and restated certificate of incorporation to effect, at the discretion of the company’s board of directors: (i) a reverse split of the company’s common stock, whereby each outstanding 5, 6, 7, 8, 9 or 10 shares of common stock would be combined and converted into one share of common stock; and (ii) for reverse splits in the range of 1-for-5 to 1-for-10, a reduction in the number of authorized shares of common stock from 200,000,000 to 80,000,000, 66,666,667, 57,142,858, 50,000,000, 44,444,445 or 40,000,0000 shares, respectively and to approve amendment to amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000 and to an amendment to the company’s 2019 equity incentive plan, or the amended 2019 plan, to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 plan by 6,000,000 shares.
BLCM Ratings Summary
BLCM Quant Ranking